Skip to content

Cardiovascular risk associated with first-line Janus kinase inhibitors versus TNF inhibitors in patients with RA: a nationwide cohort study.

Oct 2026 · Rheumatology · 0 citations
Medicine

TL;DR

First-line use of JAKi was not associated with an increased risk of MACE compared with TNFi, providing real-world evidence supporting the cardiovascular safety of JAKi as first-line advanced therapy in patients with RA.

Abstract

Objective

To compare the risk of major adverse cardiovascular events (MACE) between tumor necrosis factor inhibitors (TNFi) and Janus kinase inhibitors (JAKi) when initiated as first-line advanced therapy in patients with rheumatoid arthritis (RA).

Methods

Using the Korean nationwide claims database, we identified patients newly diagnosed with RA between 2010 and 2015. Patients who initiated TNFi or JAKi as first-line advanced therapy were selected for analysis. Patients were followed from initiation of TNFi or JAKi through June 2024. The primary outcome was incident MACE, defined as myocardial infarction, ischemic stroke, or coronary revascularization. Multivariable Cox proportional hazards models were applied in the total cohort. We additionally performed propensity score (PS)-matched analyses to address confounding by indication. Prespecified subgroup analyses were conducted according to baseline cardiovascular risk factors.

Results

The study included 6,174 patients (TNFi = 5,152; JAKi = 1,022). The incidence rates of MACE were 4.1 and 3.6 per 1,000 person-years in the TNFi and JAKi groups, respectively. MACE risk did not differ significantly between JAKi and TNFi in the total study cohort (adjusted hazard ratio [HR] 0.636, 95% confidence interval [CI] 0.283 to 1.429) or in the PS-matched population (adjusted HR 0.715, 95% CI 0.187 to 2.739). Results were consistent across all prespecified subgroups, including patients with baseline cardiovascular risk factors.

Conclusion

First-line use of JAKi was not associated with an increased risk of MACE compared with TNFi. These findings provide real-world evidence supporting the cardiovascular safety of JAKi as first-line advanced therapy in patients with RA.

View source

Similar papers

Nov 2026

Age-stratified risk of major adverse cardiovascular events with JAK inhibitors in rheumatoid arthritis: A nationwide cohort study.

BACKGROUND The cardiovascular safety of Janus kinase inhibitors (JAKi) compared with biological disease-modifying antirheumatic drugs (bDMARDs) and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis (RA) remains debated. We aimed to evaluate the risk of major adverse cardiov...

Chun-Hsin Wu, Chia-Tse Weng, Sheng-Hsiang Lin · 0 citations
Open access Sep 2026

Cardiovascular and mortality outcomes with JAK versus TNF inhibitors in rheumatoid arthritis: a target trial emulation (CARDINAL-RA)

Objectives This study aims to compare cardiovascular and mortality outcomes of Janus kinase inhibitors (JAKi) versus tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA) at elevated cardiovascular risk using target trial emulation. Methods Within TriNetX, adults with RA aged ≥50 years and ≥1 cardiovascu...

R. McClenahan, L. Alamlih · 0 citations
Open access Oct 2026

Upfront immune checkpoint inhibitors and long-term risk of major adverse cardiovascular events: a population-based propensity-matched cohort study

Findings support proactive cardiovascular risk assessment and optimization in long-term survivors while reinforcing that the excess risk is modest and should not deter use of these life-prolonging therapies.

I. Nardi Agmon, V. Giannakeas, Y. Kaliwal et al. · 0 citations
Sep 2026

Association Between PCSK9 Inhibitor Use and Risk of Incident Heart Failure in Patients With Dyslipidemia.

AIM To evaluate whether the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) is associated with a reduced 1-year incidence of new-onset heart failure (HF) compared to statins among patients with dyslipidemia. METHODS We conducted a retrospective cohort study using the TriNetX global health re...

Jheng-Yan Wu, Keng-Wei Lee, Sheng-Chi Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.